Publication of Supplementary Prospectus

RNS Number : 6328Q

BB Healthcare Trust PLC

20 February 2019

 

20 February 2019

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM) OR TO ANY NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM OR TO PROFESSIONAL INVESTORS IN IRELAND)

BB Healthcare Trust plc

Publication of Supplementary Prospectus

The Board of Directors of BB Healthcare Trust plc (the "Company") announces the publication today of a supplementary prospectus (the "Supplementary Prospectus"). The publication of the Supplementary Prospectus follows the publication of the Company's financial statements for the year ended 30 November 2018.

The Supplementary Prospectus is supplemental to, and should be read in conjunction with, the prospectus published by the Company on 5 November 2018 in relation to its share issuance programme of up to 345 million ordinary shares in aggregate (the "Share Issuance Programme").

The Supplementary Prospectus will shortly be available on the Company's website (via www.bbhealthcaretrust.com), subject to certain access restrictions, and available for inspection at the Company's registered office, at Mermaid House, 2 Puddle Dock, London EC4V 3DB. In addition, a copy of the Supplementary Prospectus will be submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM.

Enquiries:

Bellevue Advisors Limited Claude Mikkelsen Telephone: [phone] Mobile: [phone] Peel Hunt LLP Liz Yong, Helen Rennardson (Corporate Broking) Mark Thompson, Chris Bunstead (Sales) Telephone: [phone] J.P. Morgan Cazenove William Simmonds Ed Murray Eddie Nissen (Sales) Oliver Kenyon Telephone: [phone] Maitland/amo - Financial PR William Clutterbuck Jason Ochere Telephone: [phone]

Disclaimer

This announcement does not constitute a prospectus relating to the Company and does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract therefor.

Each of Peel Hunt LLP ("Peel Hunt"), which is authorised and regulated in the United Kingdom by the FCA, and J.P. Morgan Securities plc, which conducts its UK investment banking activities as J.P. Morgan Cazenove ("J.P. Morgan Cazenove"), and which is authorised by the Prudential Regulation Authority and regulated by the Prudential Regulation Authority and the FCA, is acting exclusively for the Company in connection with the matters described in this announcement and is not acting for or advising any other person, or treating any other person as its client, in relation thereto and will not be responsible to anyone other than the Company for providing the regulatory protection afforded to clients of Peel Hunt and J.P. Morgan Cazenove or for providing advice to any other person in relation to the matters contained herein.

The shares of the Company have not been and will not be registered under the US Securities Act of 1933, and may not be offered or sold in the United States. Moreover, the shares of the Company have not been, nor will they be, registered under the applicable securities laws of Australia, Canada, the Republic of South Africa, Japan or any member state of the EEA (other than the United Kingdom). Further, the Company will not be registered under the US Investment Company Act of 1940, as amended. Subject to certain exceptions, the shares of the Company may not be offered or sold in the United States, Australia, Canada, the Republic of South Africa, Japan or any member state of the EEA (other than the United Kingdom or to professional investors in Ireland) or to, or for the account or benefit of, any national, resident or citizen of the United States, Australia, Canada, the Republic of South Africa, Japan or any member state of the EEA (other than the United Kingdom or to professional investors in Ireland). The share issuance programme, and the distribution of this announcement, in other jurisdictions may be restricted by law and the persons into whose possession this announcement comes should inform themselves about, and observe, any such restrictions.  

 

END

 

 

PSPPGUQAPUPBGGU